Herm Rosenman Sells Shares of Natera, Inc. on NasdaqGS

Herm Rosenman, an insider at Natera, Inc. (NasdaqGS: NTRA), sold 16,530 shares of the company on June 24, 2026. The shares were sold at an average price of $250 each, amounting to a total transaction value of approximately $4.13 million. This sale was carried out under a pre-arranged Rule 10b5-1 trading plan.

Insider Buying and Selling at Natera, Inc.

In addition to Herm Rosenman's sale, several other insiders at Natera, Inc. have been selling shares. On June 24, 2026, Daniel Rabinowitz, the company's Secretary and Chief Legal Officer, sold 33,600 shares at an average price of $251.65. Earlier in June, other insiders like Jonathan Sheena and Rowan Chapman also sold significant amounts of shares as part of planned transactions.

Natera, Inc. Stock Down 18.4%

Shares of Natera, Inc. traded around $264.70 on Saturday. The company, with a market cap of about $37.34 billion, is part of the healthcare sector, specializing in diagnostics and research. Natera has a forward P/E of -1251.27, reflecting its current unprofitability, and a beta of 1.544, indicating higher volatility. The stock's 52-week range is between $131.81 and $271.47, with 50-day and 200-day moving averages of $211.31 and $208.15, respectively. The company maintains a current ratio of 2.96 and a quick ratio of 2.70, with a debt-to-equity ratio of 13.53.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Natera, Inc. On June 26, 2026, Bernstein reiterated its 'buy' rating with a price target of $310. BTIG maintained its 'buy' rating with a $275 target on June 24, while Barclays also kept a 'buy' rating, targeting $260 on the same day. Overall, the consensus among 20 analysts is a 'buy' recommendation, with a mean price target of $260.30.

About Natera, Inc.

Natera, Inc. is a healthcare company based in Austin, Texas, focusing on developing and commercializing molecular testing services. It offers a range of diagnostic tests, including Signatera for cancer monitoring, Panorama for prenatal screening, and Prospera for transplant assessment. Under the leadership of CEO Steven Leonard Chapman, the company employs over 6,000 people and collaborates with various laboratories and pharmaceutical companies worldwide.

Bottom Line

Insider selling at Natera, Inc. by Herm Rosenman and others highlights ongoing planned transactions by key executives. While these sales are part of pre-arranged plans, they offer insight into insider activity. Investors often monitor such transactions for potential signals, although they don't necessarily reflect current company performance. Analyst ratings remain positive, with several firms maintaining 'buy' ratings and setting high price targets, indicating confidence in Natera's future prospects.